Twenty years ago, Pfizer Inc. didn’t sell any drugs treating cancer. Now, it sells 17, including four that were approved in the U.S. at the end of last year, more than any other pharmaceutical company ...
RELATED: Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy Novartis ... These treatments involve taking a patient's T cells, modifying them to better target and attack cancer ...
The Pfizer-OncoImmune entanglement will investigate a single immunotherapy that targets CTLA-4, a protein secreted by cancer cells that blocks the activation ... factor in Agenus' existence. A few ...
Pfizer also boasts a strong biosimilars pipeline. Biosimilars in late-stage development include biosimilar versions of Roche’s RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie’s ABBV ...
Bourla, 56, the company’s chief operating officer, helped construct a path that’s already produced blockbuster cancer drug Ibrance, which now sells $3.1 billion annually. Pfizer projects regulatory ...
Among the most significant are MEDI4736, which uses the body’s own immune system to fight tumors, and AZD9291, a lung cancer treatment. The company also reported progress in drugs that treat diabetes, ...
Taking a look at the specifics, Pfizer’s management says its drugs Ibrance, which treats breast cancer, its anticoagulant Eliquis and Xeljanz, which takes aim at psoriatic arthritis, could each ...
The US drugs giant has been ordered to pay £84.2mln while its distributor Flynn has been fined £5.2mln. In a statement, the CMA said Pfizer ramped up the price of phenytoin sodium capsules by 2,600%, ...
Pfizer (PFE) reported earnings Tuesday Morning and posted stronger than expected quarterly results, helped by growing sales of its cancer drugs and increase in demand in emerging markets. After recent ...